Definium Therapeutics (DFTX) Exchange Rate Effect (2020 - 2026)
Definium Therapeutics (DFTX) reported Exchange Rate Effect of $3000.0 for Q1 2026, up 125.0% year-over-year from $1333.3 in Q1 2025, and up 200.0% on a QoQ basis from $1000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 7 years of Exchange Rate Effect data on file, last reported at $3000.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 125.0% year-over-year to $3000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8000.0 (up 138.1% YoY) and the FY2025 annual result came in at -$7000.0, up 76.67% from the prior year.
- Exchange Rate Effect improved to $3000.0 in Q1 2026 per DFTX's latest filing, from $1000.0 in the prior quarter.
- Across five years, Exchange Rate Effect topped out at $57000.0 in Q2 2023 and bottomed at -$194000.0 in Q2 2022.
- The 5-year median for Exchange Rate Effect is $1000.0 (2024), against an average of -$15529.4.
- The widest annual swing landed in 2024, when Exchange Rate Effect slumped 240.0%; it then jumped 2400.0% in 2025.
- Tracing DFTX's Exchange Rate Effect over 5 years: stood at $56000.0 in 2022, then plunged by 144.64% to -$25000.0 in 2023, then soared by 104.0% to $1000.0 in 2024, then changed by 0.0% to $1000.0 in 2025, then surged by 200.0% to $3000.0 in 2026.
- Per Business Quant, the three latest DFTX Exchange Rate Effect figures stand at $3000.0 (Q1 2026), $1000.0 (Q4 2025), and -$21000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 3.60 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -2.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -40.30 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -900,000.00 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -7.06 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 25,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Sep 30, 2024 | -11,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Dec 31, 2023 | -25,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Jun 30, 2023 | 57,000.00 |
| Jun 30, 2023 | 57,000.00 |
| Mar 31, 2023 | 15,000.00 |
| Mar 31, 2023 | 15,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Dec 31, 2022 | 56,000.00 |
| Sep 30, 2022 | -136,000.00 |
| Sep 30, 2022 | -136,000.00 |
| Jun 30, 2022 | -194,000.00 |
| Jun 30, 2022 | -194,000.00 |
| Mar 31, 2022 | -35,000.00 |
| Mar 31, 2022 | -35,000.00 |
| Dec 31, 2021 | -4.79 Mn |
| Dec 31, 2021 | -4.79 Mn |
| Sep 30, 2021 | -1.16 Mn |
| Sep 30, 2021 | -1.16 Mn |
| Jun 30, 2021 | 406,000.00 |
| Jun 30, 2021 | 406,000.00 |
| Mar 31, 2021 | 313,000.00 |
| Mar 31, 2021 | 313,000.00 |
| Dec 31, 2020 | 272,000.00 |
| Dec 31, 2020 | 272,000.00 |
| Sep 30, 2020 | 40,000.00 |
| Sep 30, 2020 | 40,000.00 |
| Jun 30, 2020 | -40,000.00 |
| Jun 30, 2020 | -40,000.00 |